HIV patients retention and attrition in care and their determinants in Ethiopia: a systematic review and meta-analysis

Nurilign Abebe Moges 1,2*, Adesina Olubukola 3, Okunlola Micheal 3 and Yemane Berhane 4

Abstract

Background: There is paucity of evidence on the magnitude of HIV patients’ retention and attrition in Ethiopia. Hence, the aim of this study was to determine the pooled magnitude of HIV patient clinical retention and attrition and to identify factors associated with retention and attrition in Ethiopia.

Methods: Systematic review and meta-analysis were done among studies conducted in Ethiopia using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Both published and unpublished studies conducted from January 1, 2005 to June 6th, 2019 were included. Major databases and search engines such as Google Scholar, PUBMED, African Journals Online (AJOL) and unpublished sources were searched to retrieve relevant articles. Data were assessed for quality, heterogeneity and publication bias. Analysis was conducted using STATA version 14 software.

Result: From a total of 45 studies 546,250 study participants were included in this review. The pooled magnitude of retention in care among HIV patients was 70.65% (95% CI, 68.19, 73.11). The overall magnitude of loss to follow up 15.17% (95% CI, 11.86, 18.47), transfer out 11.17% (95% CI, 7.12, 15.21) and death rate were 6.75% (95% CI, 6.22, 7.27). Major determinants of attrition were being unmarried patient (OR 1.52, 95% CI: 1.15–2.01), non-disclosed HIV status (OR 6.36, 95% CI: 3.58–11.29), poor drug adherence (OR 6.60, 95% CI: 1.41–30.97), poor functional status (OR 2.11, 95% CI: 1.33–3.34), being underweight (OR 2.21, 95% CI: 1.45–3.39) and advanced clinical stage (OR 1.85, 95% CI: 1.36–2.51). Whereas absence of opportunistic infections (OR 0.52, 95% CI: 0.30–0.9), normal hemoglobin status (OR 0.29, 95% CI: 0.20–0.42) and non-substance use (OR 95% CI: 0.41, 0.17–0.98) were facilitators of HIV patient retention in clinical care.

Conclusion: The level of retention to the care among HIV patients was low in Ethiopia. Socio-economic, clinical, nutritional and behavioral, intervention is necessary to achieve adequate patient retention in clinical care.

Keywords: Retention, Attrition, HIV patient, Systematic review, Ethiopia

* Correspondence: nure113@gmail.com
1Department of Public Health, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia
2Pan African University, Life and Earth Sciences Including Health and Agriculture Institute (PAULESI), University of Ibadan, Ibadan, Nigeria

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Globally, 36.7 million people were living with Human Immunodeficiency Virus (HIV) in 2016 [1]. The United Nations Programme on HIV/AIDS (UNAIDS) 90–90-90 target states that 90% of people living with HIV should know their status, 90% of people living with HIV who know their status should be on treatment, and 90% of people on treatment should be virally suppressed. A record 19.5 million people were accessing antiretroviral therapy in 2017, and for the first time, more than half of all people living with HIV are on treatment [2].

In Ethiopia, Antiretroviral treatment (ART) began in 2003 and free ART was launched in January 2005. In 2016, only 67% of HIV positive people are believed to know their status. Additionally, the treatment coverage of all HIV positive people was 59% and only 51% of all HIV positive people on highly active antiretroviral therapy (HAART) had viral suppression [1]. In 2017, an estimated 738,976 Ethiopians were living with HIV and all of them were eligible for ART treatment. However, it was reported that only 426,000 were taking ARV in the same year [3].

The estimated 36-month retention from 2008 to 2013 was; 65% in Africa, 80% in Asia, and 64% in Latin America and the Caribbean [4]. In low and middle income countries HIV patient retention at 36 months on treatment averages 65–70% [4]. Patient retention in care is a challenge in many African countries [5, 6]. Similarly, in various regions of Ethiopia, during the pre-ART era, about one third of HIV positive people receiving clinical care were lost to follow up [7, 8]. Retention in care within 12 month of treatment initiation varies from 83 to 94% in Ethiopia [9].

Qualitative studies in Addis Ababa, Bahir Dar and Gondar, Ethiopia, revealed that fear of stigma, care dissatisfaction, use of holy water, fasting, and economic constraints discouraged retention in care. Whereas social support and restored health and functional ability motivated retention [10, 11].

Though Ethiopia has improved patient retention from 2005 to 2013 [12], still there are large number of patients that discontinue from treatment [13]. Unlike other regions of the world [4], there is paucity of evidence on the rate of attrition among HIV positive patient in Ethiopia. A systematic review and meta-analysis on ART treatment discontinuation of HIV patients in Ethiopia indicated various factors are responsible for treatment discontinuation [13]. However, the study was limited to only 9 papers and only three regions out of nine regions of the country. At the same time, this previous study did not include pooled incidence and prevalence of loss to follow up, death and transfer out [13]. In addition, the study does not show the magnitude of patient retention and attrition. In view of this, we decided to investigate the retention, attrition and its determinants at national level. Patient attrition includes loss to follow up (LTF), death (D) and transfer out (TO) which is the official transfer of the patient to another clinic. Therefore, this study aimed to determine the pooled magnitude of HIV patients’ clinical retention, attrition and identify factors associated with retention and attrition.

Methods
Study design
Systematic review and meta-analysis was done using studies conducted in English language in Ethiopia. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [14] was strictly followed during search of studies and analysis process.

Eligibility criteria
We included studies conducted on adult HIV positive individuals’ retention in HIV care in Ethiopia. Studies that reported lost to follow up, defaulters and treatment discontinuation, transfer out and death were included. Studies that used any length of follow up period were eligible for this review. There was no restriction based on study designs of primary studies except systematic review and meta-analysis. Both published and unpublished primary studies from the start of ART program in January 2005 in Ethiopia to last date of literature review on June 6, 2019 were included. The reason for restriction of study period was that the first article in Ethiopia about HIV patients’ retention in clinical care data were collected in 2005 and published in 2008 and the last date of literature review search was on Jun 6, 2019. Moreover, qualitative studies which didn’t report quantitative outcomes of interest were excluded.

Search strategy
Published research was identified through a systematic search of PubMed, Google Scholar and the African Journals Online (AJOL). Information were retrieved from online published data sources and unpublished thesis works. Online databases include PubMed, Google scholar and African Journals online (AJOL). We used search terms in PubMed as (retention) OR attrition) AND HIV) OR AIDS) AND patients) OR positive people) AND Ethiopia). Moreover, keywords for review included; retention, attrition, loss to follow up, death, discontinuation, defaulters and treatment outcomes of ART in Ethiopia and were used to search additional articles. We audited the references of all articles which deemed important for our outcomes of interest. Moreover, we searched for unpublished works in the postgraduate library of Debre Markos University and other universities institutional repositories.
Study selection and quality appraisal
Studies were evaluated using title, abstract and full text. Studies that used retrospective follow up design were included only if full cohort assessment report was obtained. Quality was assessed using Critical Appraisal and Assessment of Methodological Quality of Studies for Systematic Review and Meta-analysis of Observational Epidemiological Studies Reporting Prevalence and Cumulative Incidence Data [15]. Two authors independently assessed the quality of the studies. Where disagreement occurred, studies were discussed until consensus was reached. Studies were assessed on nine dimensions and for each dimension the authors would indicate that the criteria was met or not met. In cases where there was insufficient information to determine the study could be graded “unclear.” The following criteria were used: 1. was the sample frame appropriate to address the target population? 2. Were study participants sampled in appropriate way? 3. Was the sample size adequate? 4. Were the study subjects and the setting described in detail? 5. Was the data analysis conducted with sufficient coverage of the identified sample? 6. Were valid methods used for the identification of the condition? 7. Was the condition measured in a standard, reliable way for all participants? 8. Was there an appropriate statistical analysis? 9. Was the response rate adequate, and if not, was the low response rate managed appropriately [15]. To be included in the meta-analysis, articles were required to meet at least 5 of the nine criteria. Quality appraisal table can be found in (Additional file 1).

Data extraction
Relevant data was extracted from eligible studies and entered into Microsoft Excel. Data collected included authors, year of publication, study period, study area, sample size, study design, our outcome of interest (retention, loss to follow up, transfer out and death), and length of follow up period.

Measurement of outcomes
Reported rates of retention in care, loss to follow-up, death and transfer out were collected from included studies. The rate of retention in care was defined as the rate of persons in the study who remain in care across periods of follow-up which was no missed visit of clinical schedule for more than three consecutive months. Study attrition was defined as the number of patients who were lost to follow-up, transferred out, or died [16]. While LTFU was defined as HIV positive patients who miss scheduled visits to the clinic for more than three consecutive months after the last visit [17]. Death and transfer out were defined as confirmed in the patient’s record by the clinicians who were in charge of care [18]. In order to facilitate analysis, all rates were changed into 100 person years of observation.

Where available, statistically significant measures of association were collected for factors associated with retention in care or attrition from care identified by studies included in the study. Then pooled odds ratio was calculated using frequency values from the primary studies and identified factors were classified as being either socio-demographic or clinical factors associated with patient retention or attrition.

Heterogeneity and publication bias
Study heterogeneity was assessed by calculating $I^2$ test statistics. Statistical significance was set at $p < 0.05$ $I^2$ scores were classified into low, moderate and high inconsistency based on the $I^2$ value of less than 25, 50 and 75% respectively [19]. Random effect analysis was carried out to determine the pooled estimates of patient retention and attrition. Publication bias was assessed using Egger’s test. For meta-analysis result with statistically significant publication bias, the Duval and Tweedie non-parametric trim and fill analysis using the random effect method of analysis was conducted [20].

Statistical methods and analysis
Data analysis was conducted using Stata version 14. Pooled prevalence of LTFU, death and transfer out were estimated using each study prevalence and standard error with 95% confidence interval (CI). For LTFU, we used both pooled prevalence and incidence density separately since most of the primary studies were follow up studies. Separate meta-analysis was conducted for the LTFU, death and transfer out outcomes. The result of meta-analysis was presented using forest plots. The meta-analysis was conducted using the random effects model of analysis since it minimizes heterogeneity of the included studies [21]. Subgroup analysis was conducted for the incidence rate of loss to follow up. Studies were stratified into subgroups based on length of follow up,

Results
A total of 3910 records were identified through online database. Of these, 1820 were identified through PubMed 900 were identified through Google Scholar, 980 were identified through Google Search and 200 from AJOL. An additional 2 articles were identified through unpublished sources. A total of 3912 were screened for inclusion. One hundred twenty were found to be duplicates and removed. Three thousands seven hundred ninety two were screened for inclusion and 3717 were excluded by title and abstract review. The full text of 75 articles were assessed for eligibility. Of these, only 45 articles passed the minimum quality score of 5 out of 9
Characteristics of included studies
Most (32) of the designs of the primary articles was retrospective follow up [9, 10, 16–18, 22–48], five case control [8, 49–52], six prospective cohort study [37, 53–58] and two cross sectional survey designs [59, 60]. Every region of Ethiopia was represented in the included studies. A total of 546,250 study participants were included from 45 articles Fig. 1. Moreover, study characteristics can be found in Table 1.

Magnitude of retention in HIV care
Of the 45 original articles, 32 articles reported magnitude of patient retention in HIV care in Ethiopia [8–10, 17, 23–28, 30–32, 34, 36, 37, 41–45, 48, 52–58, 60, 62, 63]. The magnitude of retention in HIV care was 70.65% (95% CI, 68.19, 73.11) with I² value of 99.9% at P-value < 0.001. The minimum retention was 32.50% (95% CI, 28.56 to 36.44) in a 9 years follow up period [24] and the maximum retention was 94% (95% CI, 90.1 to 97.7) in 1 year. The result is given in Fig. 2.

The maximum and minimum follow up period was 14 years and 3 months respectively. Except one article that used 3 months of follow up [27], all original studies used a follow up period of above 1 year. Most (19) of the studies that reported a follow up period from 2 to 5 years had average retention in care of 71.09% (95% CI, 68.75, 73.44). Furthermore, 9 articles that used more than 5 years follow up period that reported on average retention rate of 68.92% (95% CI, 65.02, and 72.81) Fig. 3.

The magnitude of attrition was an aggregations of LTFU, transfer out and death. Accordingly, the magnitude of loss to follow up was 15.17% (95% CI: 11.86, 18.47). The lowest and highest rate of loss to follow up was 3.13% (95% CI: 2.90, 3.36) and 31.40% (95% CI: 31.37, 31.43) Fig. 4.

Magnitude of attrition rate of HIV/AIDS patients in Ethiopia
Incidence of loss to follow up was 13.79/100 person years of observation (95% CI, 9.66–17.93). The incidence rate was highest in the follow up years 2 through 5 years which was 16.69/100 person years of observation, (95% CI, 6.77–26.61). Subgroup analysis of incidence rate of loss to follow up was reported by 12 papers with resulted cumulative incidence density of 13.79/100 person years of observation (95% CI, 9.66–17.93). It is higher in the follow up years ranged from 2 to 5 years 16.69/100 person years of observation, (95% CI, 6.77–26.61) Fig. 5.
Table 1 Characteristics of included articles (n = 45)

| Authors and year          | (n) | Study design   | Study area                        | Major objectives of the study                                                                 | Major findings                                                                                                                                 |
|---------------------------|-----|----------------|-----------------------------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Takele et al. [24]        | 542 | Retrospective  | Bichena Health center, Northwest, Ethiopia | To assess the time to lost follow up and its predictors among adult HIV positive people receiving ART | Prevalence of lost to follow up was 40.8% and incidence was 13.45/100 person years. Predictors of loss to follow up were: ▶ Poor drug adherence AHR, 2.91 (2.08–4.09), ▶ TDF based base line regimen AHR, 1.63 (1.20–2.20), ▶ baseline regimen change AHR, 1.79 (1.08–2.97), ▶ Poor functional status AHR, 2.71 (2.01–3.66) |
| Yigzaw et al. [22]        | 484 | Retrospective  | Debre Markos referral hospital, Northwest, Ethiopia | To determine the incidence and predictors of loss to follow up among HIV positive adults on ART | About 17.36% of the individual were lost from ART follow-up. Rate of lost to follow-up was found to be 3.7 per 100 person-years observation and 30.95% occurred within the last years of follow up. The predictors for LTFU were: ▶ ART Regimen [AZT-3TC-NVP, AHR (95% CI) = 2.79 (1.07, 7.23)], ▶ AZT-3TC-EPV, AHR (95% CI) = 3.14 (1.13, 8.08), ▶ TDF-3TC-EPV, AHR (95% CI) = 9.3 (3.75, 23.8), ▶ good ART adherence (AHR (95% CI) = 0.54 (0.3, 0.9)), ▶ WHO clinical stage IV (AHR: 95%CI = 2.75 (1.23–6.16)), ▶ Urban residence (AHR 95%CI) = 0.6 (0.37–0.99), ▶ no cell phone (AHR: 95%CI) = 1.9 (1.14–3.4), ▶ Age categories (35–44 years (AHR(95%CI) = 0.32 (0.15–0.67), ▶ 45+ years (AHR (95%CI) =0.33 (0.13–0.83)]. |
| Seifu et al. [16]         | 1439| Retrospective  | Karamara general hospital, Jigjiga town, Eastern Ethiopia | To measure incidence and predictors of loss to follow up among adult ART clients.               | The incidence rate of loss to follow up in the cohort was 26.6% (95% C); 18.1–29.6 per 100 person months. Factors associated with LTFU were: ▶ Patients with male sex (HR: 2.1; CI: 1.3–3.4), ▶ patients whose next appointment weren’t recorded (HR 1.2, 95% CI: (1.12–1.36]), ▶ patients who did not disclose their status to any one (HR 2.8, 95% CI (2.22–5.23]). |
| Berheto et al. [23]       | 8009| Retrospective  | Four health centers and 2 hospitals in Southern, Ethiopia | To examine the effects of mental health training on HIV patient retention in care.             | The incidence of attrition was 6.5 per 100 person-years. ▶ 21% higher in the unexposed group (HR 1.2; 95% CI 1.1, 1.3), ▶ Retention in care was significantly higher in the mental health trained group. Independent risk factors for attrition were: ▶ WHO clinical staging III/IV ▶ Tuberculosis co-infection ▶ the male gender ▶ Poor functional status |
| Assemie et al. [17]       | 602 | Retrospective  | Pawi General Hospital, northwest Ethiopia | To assess incidence of lost-to-follow-up and its predictors among HIV-positive adults after initiation of ART | Cumulative incidence of lost-to-follow-up after ART initiation was high, 11.6% (95% CI 9.8–13.7) per 100 adult-years follow-up time. Independent significant predictors of lost to follow up were: ▶ Being aged 15–28 years (AHR = 0.44; 95% CI 0.24–0.83), ▶ being on WHO clinical stage IV (AHR = 2.09; 95% CI 1.02–3.13), ▶ Receiving isoniazid preventive therapy (AHR = 0.11; 95% CI 0.06–0.18). |
| Authors and year         | Study design | Study area                              | Major objectives of the study                                                                 | Major findings                                                                 |
|-------------------------|--------------|-----------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Adewo et al. [25]       | Retrospective cohort | Tepi General Hospital in South West Ethiopia. | to assess factors related with time to attrition                                                 | 179 patients were lost to follow up and 37 patients died, contributing to an overall attrition of 33.13%. During the early six months the attrition rate was 89.8%.  
➢ Not starting cotrimoxazole prophylaxis (AHR = 1.51, 95% CI, 1.02–2.25)  
➢ being co-infected with tuberculosis (TB) (AHR = 2.16, 95%CI, 1.35–3.45)  
➢ living further than 10 km away from the hospital (AHR = 1.44, 95%CI, 1.07–2.0)  
➢ Not disclosed status of HIV (AHR = 3.04) were factors significantly associated with time to attrition. |
| Gesesew et al. [26]     | Retrospective cohort | Jimma University Teaching Hospital, Western Ethiopia | to assess prevalence, trend and risk factors for ART discontinuation                           | 1090 (22.3%) had discontinued, 954 (19.5%) had transferred out, 300 (6.1%) had died, 2517 (51.4%) were alive and on ART. The trend of ART discontinuation showed an upward direction in the recent times and reached a peak, accounting for a magnitude of 10%, in 2004 and 2005.  
➢ Being a female (AOR = 2.1, 95%CI: 1.7–2.8),  
➢ Having an immunological failure (AOR = 2.3, 1.9–8.2)  
➢ having tuberculosis/HIV co-infection (AOR = 1.5, 1.1–2.1)  
➢ No previous history of HIV testing (AOR = 1.8, 1.4–2.9) were the risk factors for ART discontinuation. |
| Bucciardini et al. [53] | Prospective cohort | In seven health facilities in Tigray in northern Ethiopia. | To determine predictors of patient attrition after 12 months in care                            | Kaplan–Meier estimates of retention in care were 83.9, 82.1 and 79.8% at 12, 18 and 24 months after starting ART, respectively. Attrition was mainly due to lost to follow-up (6.8%), transferred-out patients (9.5%) and mortality (4.4%). Factors associated with attrition were;  
➢ Male sex  
➢ CD4 count < 200 cells/μL  
➢ Type of health facility |
| Wilhelmson et al. [27]  | Retrospective cohort | Adama Hospital, central Ethiopia | To determine retention in care among patients receiving second-line ART in a public hospital | At the end of study follow-up, 80.5% of patients remained in care (adults and adolescents 79.8%; children 85.7%). LTFU among adults and adolescents was associated with;  
➢ baseline CD4 cell count 100 cells/mm3 and  
➢ First-line regimen failure that was not confirmed by HIV RNA testing. |
| Tiruneh et al. [10]     | Retrospective cohort | Addis Ababa, Central Ethiopia | To assessed how well patients stay in care and explored factors associated with retention       | Thirty percent were LTFU by end of the study; the median time to LTFU was 1675 days. Higher risk of LTFU was associated with;  
➢ Baseline CD4 counts < 100 and > 200 cells/μL (HR = 1.62; 95%CI: 1.03–2.55); and HR = 2.06; 95%CI: 1.15–3.70, compared with patients with baseline CD4 counts of 100–200 cells/μL.  
➢ Bedridden at baseline (HR = 2.05; 95%CI: [1.11–3.80])  
➢ Those with no or only primary education (HR = 1.50; 95%CI: [1.00–2.34]) were more likely to be LTFU.  
➢ The qualitative data revealed that |
Table 1 Characteristics of included articles (n = 45) (Continued)

| Authors and year               | (n)  | Study design     | Study area                                          | Major objectives of the study                                                                 | Major findings                                                                                     |
|-------------------------------|------|------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Megerso et al. [49]           | 1248 | Case control     | Oromia, central and western Ethiopia                | Identifying correlates of loss to follow-up in ART among adult patients                          | Fear of stigma, care dissatisfaction, use of holy water, and economic constraints discouraged retention in care. |
| Mitiku et al. [28]            | 346  | Retrospective cohort | South and North Wollo, Oromia special zone, Northern Ethiopia | To determine levels and determinants of LFU under Option B+ among pregnant and breastfeeding women | Overall, 57 (16.5%) women were LTFU. The cumulative proportions of LTFU at 6, 12 and 24 months were 11.9, 15.7 and 22.6%, respectively. ➢ The risk of LTFU was higher in younger women 18 to 24 years than 30 to 40 years: (AHR = 2.3; 95% CI: 1.2 to 4.5) ➢ In those attending hospitals compared to those attending health centers (AHR: 1.8; 95% CI: 1.1 to 3.2); ➢ In patients starting ART on the same day of diagnosis (AHR: 1.85; 95% CI: 1.1 to 3.2); ➢ Missing CD4 cell counts at ART initiation (AHR: 2.3; 95% CI: 1.2 to 4.4); |
| Teshome et al. [54]           | 1173 | Retrospective cohort | 22 hospitals and 25 health centers in southern Ethiopia. | Compared death and loss to follow-up (LTFU) rates among ART patients among patients in hospitals and health centers | 24.6% were either dead or LTFU, resulting in a retention rate of 75.4%. The death rates were 3.0 and 1.5 and the LTFU rate were 9.0 and 10.9 per 100 person-years of observation in health centers and hospitals, respectively. The competing-risk regression model showed that; ➢ The longer gap between testing and initiation of ART, ➢ Body mass index > 18.5 (AHR, 0.58 (95% CI, 0.38–0.89)) ➢ Advanced WHO clinical stage ➢ No Isoniazid prophylaxis (AHR, 1.90 (95% CI, 1.10–3.23)) ➢ Age 26–39 (AHR, 0.59 (95% CI, 0.42–0.83)) ➢ Secondary and above educational compared to no education status (AHR, 0.58 (95% CI, 0.39–0.67)) were independently associated with LTFU. ➢ Moreover, baseline tuberculosis disease, poor functional status /bed ridden (AHR, 5.35 (95% CI, 1.67–17.1)), and follow-up at a health center were associated with an elevated probability of death. |
| Dessalegn et al. [50]         | 727  | Case control     | Wukro primary public hospital, Northern Ethiopia     | To assess the magnitude and predictors of loss to follow-up among adult ART clients               | 11% of them were loss to follow up. Factors associated with LTFU were; ➢ Absence of bereavement concern AOR, 0.12 (0.046–0.30) ➢ not provided Isoniazide (INH) prophylaxis AOR, 3.04 (1.3, 7.3); ➢ The presence of side effects AOR, 12.34 (4.86, 31.35) ➢ Earlier (< 36 month) periods after |
| Authors and year                  | Study design | Study area                          | Major objectives of the study                                                                 | Major findings                                                                                           |
|----------------------------------|--------------|-------------------------------------|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Melaku et al. [30]               | 93,418       | Nation wide                         | To measure trend and treatment outcomes of HIV treatment                                         | 24% of patients were LTF before ART initiation. Among those initiating ART, attrition was 30% after 36 months, with most occurring within the first 6 months. Recorded death after ART initiation was 6.4 and 9.2% at 6 and 36 months, respectively, and decreased over time. Younger age, male gender, never being married, no formal education, low CD4+ cell count, and advanced WHO stage were associated with increased LTFU. Death was lower among younger adults, males, married individuals, with those with higher CD4+ cell counts and lower WHO stage at ART initiation. |
| Shaweno et al. [29]              | 626          | Sheka Zonal Hospital, southern Ehtiopia | time when LTFU occurs and the associated factors among adults enrolled in pre-ART care            | A total of 178 (28.4%) pre-ART patients were lost to follow up, 93% of which occurred within the first six months. The independent predictors included: ➢ Not having been started on cotrimoxazole prophylaxis (AHR = 1.77, 95% CI: 1.12–2.79), ➢ Baseline CD4 count of or above 350 cells/mm³ (AHR = 1.87, 95% CI: 1.02–3.45), ➢ An undisclosed HIV status (AHR = 3.04, 95% CI: 2.07–4.45). |
| Mekuria et al. [31]              | 836          | Addis Ababa, Central Ethiopia        | To describe the proportion of patients who are retained in HIV care and characterize predictors of attrition among HIV-infected adults receiving cART | Nearly 80% (95% CI: 76.7, 82.1%) of the patients were retained in care in the first 3 and half years of antiretroviral therapy. After successfully tracing more than half of the LTFU patients, the updated one year retention in care estimate became 86% (95% CI: 83.4, 88.1%). ➢ Severe immune deficiency at enrolment in care/or at ART initiation ➢ ‘bed-ridden’ or ‘ambulatory’ functional status at the start of ART predicted attrition. |
| Bucciardini et al. [55]          | 563          | Tigray, Northern Ethiopia            | We report data on retention in care and its associated determinants                              | Overall 85.1% of their patients retained after one year from starting ART. Loss to follow up (5.5%) and transfers to other health facilities (6.6) were the main determinant of attrition. The factors associated with retention were: ➢ The type of health facilities, ➢ Active TB (HR 1.72, 95% CI: 1.23–2.41), ➢ Male gender (AHR 1.34 (95% CI), 1.04 to 1.74. |
| Assefa et al. [32]               | 11,371       | three health facilities in Addis Ababa, Central Ethiopia | To identify the level of long-term outcomes and their determinants in patients on ART in Ethiopia | Retention rates were 82, 74, and 72% at 24, 60, and 84 months on ART, respectively. Retention was associated with: ➢ Male sex, adolescent age, marital status, advanced HIV disease, illiteracy and peer-support services ➢ However, long-term retention was associated independently with: ➢ only male sex (AHR 0.68 [0.56 to 0.77]) ➢ married patients [with AHR 0.62 (0.54 to 0.72)] ➢ peer-support services [with AHR 1.62 (1.58 to 1.66)] |
| Authors and year | n  | Study design  | Study area                      | Major objectives of the study                                                                 | Major findings                                                                                                                                                                                                                                                                                                                                 |
|-----------------|----|---------------|---------------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Berheto et al.  | 2133 | retrospective | Mizan-Aman General Hospital in the Southern Ethiopia | aimed at determining the incidence and risk factors for LTFU in HIV patients on ART | Around 574 (26.7%) patients were defined as LTFU. The cumulative incidence of LTFU was 8.8 (95% CIs 8.1–9.6) per 1000 person months. ▶ Patients with regimen substitution (HR 5.2; 95% CIs 3.6–7.3), ▶ Never took isoniazid (INH) prophylaxis (HR 3.7; 95% CIs 2.3–6.2), ▶ adolescent (HR 2.1; 95% CIs 1.3–3.4), ▶ Had a baseline CD4 count < 200 cells/mm³ (HR 1.7, 95% CIs 1.3–2.2) were at higher risk of LTFU, WHO clinical stage III (HR 0.6; 95% CIs 0.4–0.9) and IV (HR 0.8; 95% CIs 0.6–1.0) patients at entry were less likely to be LTFU than clinical stage I patients ▶ Ambulatory and bedridden functional status were less affected by LTF than working groups (HR, 0.4 (0.3,0.6) and HR, 0.7 (0.5, 0.9)) respectively ▶ There was no significant difference in risk of LTFU in males and females in this study |
| Reepalu et al.  | 678 | Prospective  | Five health centers in Adama, Central Ethiopia | compared virological suppression (VS) rates, mortality, and retention in care in HIV-positive adults receiving care | No difference in retention in care between TB and non-TB patients was observed during follow-up; 25 (3.7%) patients died, and 17 (2.5%) were lost to follow-up (P = .30 and P = .83, respectively). |
| Tadesse et al.  | 520 | retrospective | Tigray, Northern Ethiopia | To determine loss to follow up and its determinants | 51 (9.8%) were lost giving a LTFU rate of 8.2 per 100 person-years. From these LTFU, 21 (41%) occurred within the first 6 months of ART initiation. The independent predictors of LTFU of patient were: ▶ being smear positive pulmonary TB [AHR (95% CI) = (2.05 (1.02, 4.12)], ▶ male gender [AHR (95%CI) = (2.73 (1.31, 5.66)], ▶ regimen AZT-3TC-NVP [AHR (95%) = (3.47 (1.02, 11.83)] and ▶ Weight ≥ 60 kg [AHR (95% CI) = (3.47 (1.02, 11.83)]. |
| Wubshet et al.  | 3012 | Cross sectional | Gondar, Northwest Ethiopia | To determine the outcome and factors associated with LTF among HIV patients | Out of the 551 patients LTF, 486 (88.20%) were successfully tracked. Death was the most common reason accounted for 233 (47.94%) of the lost to follow-up. Reasons for non-deaths losses include: stopped antiretroviral treatment due to different reasons, 135 (53.36%), and relocation to another antiretroviral treatment program by self-transfer, 118 (46.64%). The rate of mortality in the first six months was 72.12 per 100 person-years (95% CI: 61.80–84.24) but this sharply decreased after 12 months to 7.92 per 100 person-years (95% CI: 4.44–14.41). Baseline clinical characteristics were strongly associated with outcome such as presence of tuberculosis infection at ART initiation, functional status (both ambulatory and bed ridden); CD4 cell count, 100 cells/mL, and WHO stage III and IV were strongly associated with mortality. On the other hand, male sex, bedridden functional status and |
## Table 1  Characteristics of included articles (n = 45) (Continued)

| Authors and year | (n) | Study design | Study area | Major objectives of the study | Major findings |
|------------------|-----|--------------|------------|------------------------------|---------------|
| Asefa et al. [51] | 236 | Case control | Nekemte Hospital, western Ethiopia | to assess determinants of defaulting from antiretroviral treatment | residence outside Gondar town were significantly associated with non-death losses. After controlling for possible confounders, ➢ living far from the facility (out of the town) (AOR = 4.1; 95%CI 1.86 to 9.42), ➢ dependent patients for source of food (AOR = 13.9; 95%CI 4.23 to 45.98), ➢ patients with mental status not at ease (AOR = 4.7; 95%CI 1.65 to 13.35), ➢ patients whose partners were HIV negative (AOR = 5.1; 95%CI 1.59 to 16.63), ➢ patients whose partners HIV status were unknown or not tested (AOR = 2.8; 95%CI 1.23 to 6.50), ➢ Patients that fear stigma (AOR = 8.3; 95%CI 2.88 to 28.33) were statistically significant association. |
| Ahmed et al. [8] | 1817 | Case control | Gondar, Northwest Ethiopia | To investigate factors associated with pre-ART LTFU in Ethiopia. | factors were found to be independently associated with pre-ART LTFU: ➢ male gender (AOR) = 2.00 (95% CI: 1.15, 3.46), ➢ higher baseline CD4 cell count (251–300 cells/μl (AOR = 2.64 (95% CI: 1.05, 6.65)), 301–350 cells/μl (AOR = 5.21 (95% CI: 1.94, 13.99)), and > 350 cells/μl (AOR = 12.10 (95% CI: 6.33, 23.12)) compared to CD4 cell count of ≤ 200 cells/μl ➢ Less advanced disease stage (WHO stage I (AOR = 2.81 (95% CI: 1.15, 6.91)) compared to WHO stage IV), ➢ Married patients (AOR = 0.39 (95% CI: 0.19, 0.79)) had reduced odds of being LTFU. ➢ Patients whose next visit date was not documented on their medical chart (AOR = 241.39 (95% CI: 119.90, 485.97)) |
| Wubshet et al. [60] | 3012 | Survey | Gondar, Northwest Ethiopia | to evaluate mortality, loss to follow up, and retention in care | 61.4% of the patients were retained on treatment, 10.4% died, and 31.4% were lost to follow up. Fifty-six percent of the deaths and 46% of those lost to follow up occurred in the first year of treatment. ➢ Male gender (AHR) 3.26; 95% CI: 1.15, 8.91) compared to WHO stage IV, ➢ Married patients (AHR = 0.39 (95% CI: 0.19, 0.79)) had reduced odds of being LTFU. ➢ Patients whose next visit date was not documented on their medical chart (AOR = 241.39 (95% CI: 119.90, 485.97)) |
| Assefa et al. [36] | 37,466 | retrospective cohort | Nationwide study | Intended to evaluate the outcomes of the ART services in 55 health facilities in Ethiopia. | Health facilities were able to retain 29,893 (80%), 20,079 (74%) and 5069 (68%) of their patients after 6, 12 and 24 months on ART, respectively. Retention rates vary across health facilities. |
Table 1: Characteristics of included articles (n = 45) (Continued)

| Authors and year | (n) | Study design | Study area | Major objectives of the study | Major findings |
|------------------|-----|--------------|------------|------------------------------|---------------|
| Balcha et al. [37] | 1709 | Prospective cohort | Oromia region | to compare the outcomes of antiretroviral therapy (ART) between hospital and health center levels | facilities, ranging from 51 to 85% after 24 months on ART. Mortality was 5, 6 and 8% after 6, 12 and 24 months on ART. More than 79% of patients with available CD4-cell counts had a baseline CD4-cell counts less than 200 cells per micro-liter of blood. |
| Deribe et al. [52] | 1270 | Case control | Jimma University Teaching Hospital, western Ethiopia | To determine the prevalence of and factors associated with defaulting from antiretroviral treatment (ART) | Of 1270 patients who started ART, 915 (72.0%) were active ART users and 355 (28.0%) had missed two or more clinical appointments. The latter comprised 173 (13.6%) defaulter, 101 (8.0%) who transferred out, 75 (5.9%) who died, and 6 (0.5%) who restarted ART. Reasons for defaulting were unclear in most cases. Reasons given were; loss of hope in medication, lack of food, Mental illness, holy water, no money for transport and other illnesses. Tracing was not successful because of incorrect address on the register in 61.6% of the cases. ➢ Taking hard drugs (cocaine, cannabis and IV drugs) ➢ excessive alcohol consumption ➢ Being bedridden, ➢ living outside Jimma town ➢ Having an HIV negative or unknown HIV status partner were associated with defaulting ART. |
| Abebe et al., [18] | 640 | Retrospective cohort | Debre Markos referral hospital, Northwest Ethiopia | To determine Survival status of HIV positive adults on antiretroviral treatment | 640 patient cards (379 alive and 261 death) adult HIV infected individuals were included in the study. General mean estimated survival time of patients after HAART initiation was improved. Significant predictors of mortality after HAART initiation were: Lower baseline hemoglobin; Ambulatory and bed ridden functional status; Poor ART adherence; Advanced WHO clinical stage; Absence of recent TB prophylaxis; Unrecognized side effects; Persistent unexplained chronic diarrhea (> 1 month) |
| Ahmed et al. [47] | 503 | Retrospective cohort | Afar, north-east Ethiopia | assessed the incidence of tuberculosis (TB) and its predictors among adults living with HIV/AIDS | 40 transfer out to other health facilities 13 died 21 loss to follow up 258 did not develop TB 119 developed TB |
| Authors and year | (n)  | Study design   | Study area                      | Major objectives of the study                                                                 | Major findings                                                                                                                                                                                                 |
|-----------------|------|----------------|---------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mekonnen et al. [46] | 1533 | Retrospective cohort | Jimma hospital southwest Ethiopia | to assess reasons and predictors of regimen change from initial highly active antiretroviral therapy | One in two (47.7%) adults changed their antiretroviral therapy regimen. Patients who were above the primary level of education [Hazard ratio (HR) 1.241 (95% CI 1.070–1.440)] and with human immunodeficiency virus/Tuberculosis co-infection [HR 1.405 (95% CI 1.156–1.708)] had the higher risk of regimen change than their comparator. |
| Chaka et al. [40] | 248  | Retrospective cohort | Adama, Central Ethiopia         | to assess Option B+ PMTCT service intervention outcomes.                                        | Loss to follow-up from the Option B+ continuum was 10 (4.2%).                                                                                                                                              |
| Tadege [41]     | 1512 | Retrospective cohort | Mettu Karl Hospital, southwest Ethiopia | to determine the major risk factors of antiretroviral therapy dropout                         | the risk of dropout for patients with primary education status was 105.8% greater as compared to illiterate (p < 0.0110). The probability of dropout for patients with marital status separated was about 16.8% higher than those patients with marital status divorced (p < 0.0070). Being merchant, farmer and daily labour had a greater risk of dropout as compared to a housewife. |
| Gezea et al. [39] | 305  | Retrospective cohort | Mekelle, Northern Ethiopia       | aimed at investigating the incidence and predictors of LTFU of TB/HIV co-infected patients      | 45 of 305 (14.8%) of TB/HIV co-infected adults were LTFU with an incidence rate of 4.5 new LTFUs per 100 Person Years (PYs) and a median follow up time of 3.1 years (Inter quartile Range (IQR): 0.8–5.3 Years). Hemoglobin level ≤ 11.0 g/dl (AHR = 2.660; 95%CI: 1.459–4.848), and any history of OIs (AHR = 3.795; 95%CI: 1.165–12.364) were risk factors of LTFU. While, adverse drug events (AHR = 0.451; 95%CI: 0.216–0.941), TB treatment completion (AHR = 0.121; 95% CI: 0.057–0.254), and being on Isoniazid Preventive Therapy (IPT) (AHR = 0.085; 95%CI: 0.012–0.628) had protective effect against LTFU. |
| Mekonnen et al. [38] | 569  | Retrospective cohort | Gondar, Northwest Ethiopia       | to estimate the incidence of lost to follow up from ART care and identify the associated factors among HIV infected patients after first-line ART initiation | The overall incidence rate of lost to follow up was 12.26 per 100 person years (95% CI (10.61–14.18)). Being underweight (< 18.5 kg/m2) (AHR 1.52, 95% CI 1.01–2.28), jobless (AHR 2.22, 95% CI 1.2–4.11), substance abuser (AHR 1.84 95% CI 1.19–2.86), having sub-optimal adherence (fair/poor) (AHR 6.33, 95% CI (3.90–10.26)), not receiving isoniazid prophylaxis (AHR 2.47, 95% CI (1.36–4.48), ambulatory functional status (AHR 1.94, 95% CI (1.23–3.06)), having opportunistic infections (AHR 1.74 95% CI 1.11–2.72), having CD4 count 201–349 cells/μL (AHR 0.58, 95% CI (0.38–0.88)) were found to be significant predictors of lost to follow up from ART service. |
| Abebe Moges et al. BMC Infectious Diseases (2020) 20:439 | 784  | Retrospective cohort | Kharamara hospital, Somalia, Eastern Ethiopia | to assess survival and identify predictors of death in adult HIV-infected patients initiating ART | There were 87 (11.1%) deaths yielding an overall mortality rate of 5.15/100 PYO (95% CI: 4.73–6.37). The estimated mortality was 8.4, 9.8, 11.3, 12.7 and 14.1% at 6, 12, 24, 36 and 48 months respectively. The independent predictors of death were single marital status (AHR: 2.31; 95%CI: 1.11–4.50), being underweight (< 18.5 Kg/m2) (AHR: 2.78–12.16), advanced WHO stage (AHR: 7.36; 95%CI: 3.17–17.12), BMI < 18.5 Kg/m2 (AHR: 2.20; 95%CI: 1.18–4.09), CD4 count < 50 cells/μL (AHR: 2.01; 95%CI: 1.03–3.95) and being resident in rural area (AHR: 1.94; 95%CI: 1.10–3.46). |
| Authors and year | (n) | Study design | Study area | Major objectives of the study | Major findings |
|-----------------|-----|--------------|------------|------------------------------|---------------|
| Ayele et al. [43] | 730 | Retrospective cohort | Kembata and Hadiya zones | To assess treatment outcomes and its determinants for HIV patients on ART | A total of 92 (12.6%) patients died, 106 (14.5%) were lost to follow-up, and 109 (15%) were transferred out. Sixty three (68%) deaths occurred in the first 6 months of treatment. The median survival time was 25 months with IQR [9, 43]. After adjustment for confounders, WHO clinical stage IV (HR 2.42; 95% CI, 1.19, 5.86), baseline CD4 lymphocyte counts of 201 cell/mm³ and 350 cell/mm³ (HR 0.20; 95% CI; 0.09–0.43), poor regimen adherence (HR 2.70 95% CI: 1.28–5.80), severe anemia (AHR: 4.57; 95%CI: 2.30–9.10), and TB co-infection (AHR: 2.30; 95%CI: 1.28–4.11) |
| Bezabh et al. [57] | 337 | Retrospective cohort | Bahrdar and Gondar, northwest Ethiopia | To determine patient, regimen, disease, patient-provider, and healthcare-related factors associated with adherence with ART | 130 (75.6%) had ≥95% adherence. In the multivariate analyses, a higher baseline BMI (OR, 1.2; 95% CI 1.0, 1.4) and use of reminder devices (OR, 9.1; 95% CI 2.0, 41.6) remained positively associated with adherence |
| Awoke et al. [42] | 2386 | Retrospective cohort | Gondar, northwest Ethiopia | To determine and compare the long-term response of patients on nevirapine and efavirenz | 70.58% were retain in clinical care 302 were transfer out to other health facilities 230 were lost to follow up 170 were dead |
| Mekuria et al. [48] | 870 | Retrospective cohort | Addis Ababa, Central Ethiopia | To investigated virological suppression levels and its predictors of detectable viraemia | A total of 656 (75.4%) patients, who were alive, were retained in HIV care. Virological suppression levels can be high in an established ART programme in a resource-limited setting |
| Assefa et al. [9] | 20,099 | Retrospective cohort | Nation wide | To reviews the performance of the ART program in Ethiopia | The ART program has been successful over several critical areas: (1) ART coverage improved from 4 to 54%; (2) the median CD4 count/mm³ at the time of ART initiation increased from 125 in 2005/6 to 231 in 2012/13; (3) retention in care after 12 months on ART has increased from 82 to 92%. In spite of these successes, important challenges also remain: (1) ART coverage is not equitable among regions (5.6–93%), between children (25%) and adults (60%), and between female (54%) and male patients (69%); (2) retention in care is variable among regions (83–94%); and, (3) the shift to second-line ART is slow and low (0.58%). |
| Lifson et al. [56] | 142 | Prospective cohort | Arbaminch | The effects of community based support on patient retention | Community health support workers (CHSWs) provided HIV and health education, counseling/social support, and facilitated communication with the HIV clinics. With 7 deaths and 3 transfers, the 12-month retention rate was 94% (95% CI 1.89–97%), and no client was LTFU in the project. Between enrollment and 12 months, clients had significant (P < .001) improvements in HIV knowledge (1.7% increase), physical and mental quality of life (81 and 21% increase), internalized |
Most common contributing factors for patient attrition was loss to follow up (15.17%), transfer out (12%) and death (5.71%) respectively Table 2.

Mortality of HIV patients in Ethiopia
Overall mortality of HIV patients in this meta-analysis was 6.75% (95% CI: 6.22, 7.27). Mortality rates were lowest in the first years of follow up (4.4% (95% CI: 0.72, 8.16)) and highest when follow up exceeded 5 years (7.65% (95% CI: 6.38, 8.92)). Pooled mortality rates are shown in Fig. 6.

HIV patients transfer out from one to other health facility
About 11.17% (95% CI: 7.12, 15.21) of all study subjects transferred out during the study period. The cumulative transfer out percentage was lowest in the earliest years of follow up, and highest by the end of the follow-up period. 5.18% (95% CI: 1.60, 8.76) and 18.35% (95% CI: 13.60, 23.11) Fig. 7.

Factors related to patient retention and attrition
Socio-demographic and behavioral factors
Five original papers stated that marital status was associated with patient retention in clinical care. Of which three articles reported that married people were less likely to be lost to follow up [8, 30, 51] and the probability of dropout for patients with separated marital status was about 16.82% higher than those patients with marital status divorced [41]. Another article [44] reported as single marital status as an independent predictor of death. Pooled odds ratio from 13 primary studies indicated that currently unmarried people are 1.52 times more likely not to be retained in clinical care (OR, 1.52, 95% CI, 1.15–2.01). Moreover, ten papers reported that male patients were less likely to be retained in HIV care in Ethiopia [8, 16, 23, 30, 33, 36, 53, 55, 59, 60]. Yet, one study in Ethiopia reported that females were less likely to be retained in clinical care [26]. However, it was not statically significant from pooled analysis of odds ratio from 18 primary studies (OR, 1.12, 95% CI, 0.97–5.45). Similarly, eight papers [17, 22, 23, 28, 30, 36, 49, 54] reported that young age was an important predictor of loss to follow up but this was not statistically significant in the pooled analysis (OR, 0.88, 95% CI, 0.27–2.89). Four papers reported that educational status had an influence on retention in care [10, 30, 41, 54]. All except one [41] primary articles has reported that people with no or primary education were more likely to experience loss to follow up compared to those with secondary and above educational level. Two studies reported that urban residents were better in retention than their rural counterparts [22, 49]. Three papers indicated that economic constraints such as being dependent patients for source of food and daily laborers were risk factors for treatment interruption [10, 49, 51]. Being a merchant, farmer, daily labour and jobless had a greater risk of dropout [38, 41]. On the other hand, one study reported that merchants were at higher risk of death [45] However, except
marital status, none of the socio-demographic factors were found statistically significant for patient retention in care (Table 3).

HIV patients who did not disclose their HIV status were 6.36 times more likely to experience attrition from clinical care (OR, 6.36, 95% CI, 3.58–11.29). Patients who were not substance users were 59% more likely to be retained in clinical care (OR, 0.41, 95% CI, 0.17–0.98). Mental health issues such as taking hard drugs (cocaïne, cannabis and IV drugs) and excessive alcohol drinking were risk factors for treatment defaulting [52]. Any types of substance use was reported as risk for loss to follow up [38]. It was also reported that patients with higher score for stress were poor in ART adherence [57]. Moreover, patients with mental status being not at ease were at increased risk for loss to follow up [51] (Table 3).

### Clinical related factors

Fourteen studies [10, 18, 23, 24, 31, 35, 38, 43, 44, 54, 57–60] indicated that poor functional status (ambulatory or bed ridden) was a factor for patient attrition (OR, 2.11, 95% CI 1.33–3.34). Twelve papers [17, 18, 22, 23, 30, 43–45, 49, 54, 58, 59] reported that patients with advanced WHO clinical stages III or IV were also at greatest risk of death and loss to follow up (OR, 1.85, 95% CI, 1.36–2.51). Seventeen papers [8, 10, 27, 29–31, 35, 38, 43–45, 49, 55, 57–60] reported that baseline CD4 count less than 200 cells/µL and greater than 350 cells/µL was reported as risk factor for attrition but it was not significant in the pooled odds ratio analysis (OR, 1.09, 95% CI,0.49–2.41). Four papers reported that lower level of hemoglobin is a risk factor for death [18, 39, 43, 44]. Four studies reported that lower weight and BMI is risk factor for patient death and loss to follow up [38, 44, 45, 57].

### Table 3

| Study ID       | ES (95% CI) | % Weight |
|---------------|------------|----------|
| Annum et al. (2018) | 32.50 (28.56, 36.44) | 3.02 |
| Berhe2 et al (2018) | 46.46 (45.36, 47.56) | 3.25 |
| Serfu et al (2018) | 85.20 (85.16, 85.24) | 3.27 |
| Assemie et al (2018) | 73.25 (69.72, 76.78) | 3.06 |
| Telele et al (2018) | 79.95 (77.30, 82.60) | 3.15 |
| Tedege (2018) | 84.80 (81.92, 87.68) | 3.13 |
| Adewo et al (2018) | 66.87 (63.26, 70.48) | 3.06 |
| Gesessew et al (2017) | 51.40 (49.77, 53.03) | 3.22 |
| Lifson et al (2017) | 94.00 (90.10, 97.90) | 3.02 |
| Assefa et al (2017) | 92.00 (91.63, 92.37) | 3.27 |
| Bucciardini et al (2017) | 79.80 (77.53, 82.07) | 3.18 |
| Wilhelmson et al (2016) | 79.80 (75.78, 83.82) | 3.01 |
| Tiruneh et al (2016) | 57.70 (51.19, 64.21) | 2.66 |
| Mekuria et al (2016) | 75.40 (72.54, 78.26) | 3.13 |
| Awoke et al (2016) | 70.58 (68.76, 72.40) | 3.21 |
| Bezabih et al (2016) | 51.04 (45.71, 56.37) | 2.84 |
| Miliku et al (2016) | 79.48 (75.23, 83.73) | 2.98 |
| Ayale et al (2015) | 57.90 (54.31, 61.49) | 3.06 |
| Damlow et al (2015) | 43.90 (40.43, 47.37) | 3.07 |
| Melaku et al (2015) | 70.00 (69.61, 70.39) | 3.27 |
| Tesfom et al (2015) | 66.00 (63.30, 68.70) | 3.15 |
| Mekuria et al (2015) | 79.04 (76.28, 81.80) | 3.14 |
| Bucciardini et al (2015) | 85.10 (82.16, 88.04) | 3.12 |
| Assefa et al (2015) | 72.00 (71.18, 72.82) | 3.26 |
| Assefa et al (2014) | 92.00 (91.90, 92.10) | 3.27 |
| Reepalu et al (2014) | 83.49 (80.69, 86.29) | 3.14 |
| Tadesse et al (2014) | 72.80 (68.98, 76.62) | 3.03 |
| Ahmed et al (2013) | 70.80 (68.70, 72.90) | 3.19 |
| wubshet et al (2012) | 61.40 (59.66, 63.14) | 3.22 |
| Assefa et al (2011) | 68.00 (67.53, 68.47) | 3.17 |
| Balch et al (2010) | 81.00 (58.69, 63.31) | 3.18 |
| Deribe et al (2008) | 72.00 (69.53, 74.47) | 3.17 |
| Overall (I-squared = 99.9%, p = 0.000) | 70.65 (68.19, 73.11) | 100.00 |

NOTE: Weights are from random effects analysis
Treatment related factors such as baseline ART regimen of Zidovudine-Lamivudine-Nevirapine (AZT-3TC-NVP) was key factor for patient attrition [22, 33]. Six studies [18, 22, 24, 38, 43, 57] demonstrated that poor drug adherence was a risk factor for patient attrition of both loss to follow up and death (OR, 6.60, 95% CI 1.41–30.97). Three studies reported that adverse drug side effects are responsible for patient loss to follow up and death [18, 39, 57]. Six studies reported that opportunistic infection were the main responsible factors for patient death and loss to follow up includes [38, 39]. These included TB [39, 44–46] and diarrhea for more than 3 months led a risk of death [18]. Nine papers reported that provision of isoniazid preventive therapy (IPT) [17, 18, 35, 38, 39, 50, 54] and CPT [25, 29] prophylaxis indicted that optimize patient retention.

Two papers reported on quality of care indicated that patients whose next appointment weren't recorded were at risk of loss to follow up [8, 16]. Three papers reported that loss to follow up was higher among HIV patients in hospitals compared to health centers [28, 37, 54] while, one study reported that loss to follow up was higher among patients attending health centers than those in hospitals [53]. On the other hand, two studies reported...
The contrary result one as higher death rate in health centers than in hospitals and other is vice versa [37, 54]. The pooled odds ratio indicated that there is no difference on level of retention based on health facility (OR, 1.23, 95% CI, 0.58–2.62) Table 4.

**Discussion**

This systematic review and meta-analysis investigated available evidence on the magnitude and associated factors of HIV patient retention and attrition in clinical care in Ethiopia.

The study indicated that the pooled prevalence of HIV patients’ clinical retention was 70.65%; and attritions was 15.17% loss to follow up, 6.75% death, and 11.17% transfer out. Furthermore, the incidence of loss to follow up was 13.79 person years of observation. Factors such as being currently unmarried, non-disclosed of HIV status, history of poor drug adherence, poor functional status, presence of opportunistic infections, lower BMI, substance use, lower hemoglobin and advanced WHO clinical stages were significantly associated with patient attrition.
Levels of HIV patient retention in antiretroviral treatment program in Ethiopia (70.65%) was comparable to the report from a study in India (70.7%) [64]. On the other hand, it was lower than patient retention in Asia (80%) [4], Sub Saharan Africa (77.5%) and Cape Town, South Africa 94% [65–67], Anambra, Nigeria (80%) [68], KwaZulu-Natal, South Africa (77.5%) [69], Khayelitsha, South Africa (85.9%) [5] and Southeastern United States (91.7%) [70]. This could be explained by the inclusion in our analysis of studies with longer follow-up periods. The longer the follow up period the lower the rates of clinical retention [69]. In addition, other possible reasons for the observed differences include the fact that countries have different levels of infrastructure, HIV burden,
and HIV associated stigma that can cause loss to follow and transfer out to other health facilities [71].

On the other hand, the level of patient retention in this study is higher than that observed studies conducted among HIV infected patients from Africa (65%), Latin America and Caribbean (64%) [4], Asia-Pacific Region [72], Tanzania (25%) [73] and South Africa [74]. In Africa, Asia, and Latin America that the value ranged from 3.1 to 45.1% [75]. The reason might be the differences in cut off point for loss to follow up (LTFU) and treatment eligibility criteria of the latter two studies. Now a days, immediate initiation of ART following HIV positive test result may contributed for good patient retention [66, 74, 76–78]. This might be due to test and treat strategy is effective in patient retention since it decreases the chance of loss to follow up from determining treatment eligibility to adherence preparation [79, 80].

Fig. 6 Magnitude of HIV patient mortality in Ethiopia from 2005 to 2019

| Study ID | ES (95% CI) | % Weight |
|----------|-------------|----------|
| > 5 years |             |          |
| Anmut et al. (2018) | 6.60 (6.51, 6.69) | 3.45 |
| Seifu et al. (2018) | 6.58 (6.55, 6.61) | 3.45 |
| Berhe et al (2018) | 10.58 (10.57, 10.59) | 3.45 |
| Tadege (2018) | 15.17 (15.05, 15.29) | 3.45 |
| Gesessew et al (2017) | 6.10 (6.09, 6.11) | 3.45 |
| Tiruneh et al (2016) | 2.60 (2.46, 2.74) | 3.44 |
| Assefa et al (2015) | 9.50 (9.49, 9.51) | 3.45 |
| Abebe et al (2014) | 4.08 (4.02, 4.14) | 3.45 |
| Subtotal (I² = 100.0%, p = 0.000) | 7.65 (6.38, 8.92) | 27.59 |
| 2 to 5 years | | |
| Assemnie et al (2018) | 4.20 (4.14, 4.26) | 3.45 |
| Telele et al (2018) | 8.56 (8.50, 8.62) | 3.45 |
| Ahmed et al (2018) | 2.88 (2.81, 2.95) | 3.45 |
| Bucciardini et al (2017) | 4.40 (4.37, 4.43) | 3.45 |
| Mekuria et al (2016) | 8.05 (7.99, 8.11) | 3.45 |
| Awoke et al (2016) | 7.12 (7.04, 7.20) | 3.45 |
| Ayele et al (2015) | 12.60 (12.51, 12.69) | 3.45 |
| Damtew et al (2015) | 11.00 (10.92, 11.08) | 3.45 |
| Melaku et al (2015) | 9.09 (9.00, 9.09) | 3.45 |
| Mekuria et al (2015) | 6.60 (6.54, 6.66) | 3.45 |
| Tadesse et al (2014) | 8.85 (8.74, 8.96) | 3.45 |
| Reepalu et al (2014) | 3.70 (3.65, 3.75) | 3.45 |
| Wubshet et al (2012) | 7.20 (7.18, 7.22) | 3.45 |
| Assefa et al (2011) | 8.00 (7.99, 8.01) | 3.45 |
| Deribe et al (2008) | 5.60 (5.56, 5.64) | 3.45 |
| Subtotal (I² = 100.0%, p = 0.000) | 7.18 (6.51, 7.86) | 51.75 |
| <= 1 years | | |
| Lifson et al (2017) | 5.00 (4.70, 5.30) | 3.41 |
| Wilhelmsen et al (2016) | 0.60 (0.56, 0.64) | 3.45 |
| Bezabih et al (2016) | 3.56 (3.45, 3.67) | 3.45 |
| Teshome et al (2015) | 4.00 (3.97, 4.03) | 3.45 |
| Bucciardini et al (2015) | 2.50 (2.45, 2.55) | 3.45 |
| Balch et al (2010) | 11.00 (10.96, 11.04) | 3.45 |
| Subtotal (I² = 100.0%, p = 0.000) | 4.44 (0.72, 9.16) | 20.66 |
| Overall (I² = 100.0%, p = 0.000) | 6.75 (6.22, 7.27) | 100.0 |

NOTE: Weights are from random effects analysis
In this study, rate of HIV patients lost to follow up, death and transfer out is similar with study report from India [64] but higher than study from Australia and Asia [81]. Loss to follow up was the major cause of attrition, followed by death and transfer out. This is in line with a previous systematic review in sub-Saharan Africa [67]. On the other hand, rate of lost to follow up (13.79 per 100 person years of observation) was lower than observed from previous studies from Asia Pacific region (21.4 person years of observation) [72], Malawi (26 and 48 per 100 person years of observation for pre-ART and ART patients respectively), Guinea-Bissau (51.1 per 100 person-years of observation) [82] and study conducted among children in Ethiopia 29.7% [7]. The reason can be due to difference of study population and the current study was composite of both earlier and recent times study findings while the previous study was conducted at the beginning of the treatment. Moreover patient retention was better in Asia than Africa from previous study [61] that reflects country specific difference in terms of patients retention. Moreover, the pooled death rate was 6.75% which is lower than previous systematic review 5–40% of death in Ethiopia [83]. The variation may be due to small sample size in the previous study and different time of follow up.

Our review identified a number of socio-demographic and clinical factors that could be targets for future interventions. It is indicated that currently unmarried people
(never married, separated, divorced and widowed) were 1.52 times more likely not to be retained in care. This is similar with a study in South Africa that reported women without regular partner were not retained in clinical care [69]. This might be because of married people get support from their spouse to adhere to their treatment. Likewise, those who did not disclose their HIV status to someone were 6.36 times more likely not to be retained in care. This can be explained by the fact that those who disclosed their sero-status can get support from someone who knew the HIV status and this facilitates regular treatment attendance. This might be due to people who had perceived HIV related stigma are more likely to experience treatment attrition [13]. Therefore, partner testing, HIV status disclosure and mutual support are important components of HIV intervention [3, 84]. In contrast to these findings, one study in Nigeria showed that married women were poor in clinical retention [68]. These differences may be due to difference by cultural practices and the attitude of people on the role of gender in both countries.

Substance abuse and mental distress have negative effects on HIV patient retention in clinical care. This finding is in line with a systematic review in developing countries [85]. This might be due to poor drug adherence as a result of distressed mental status. Retention in care was significantly higher in patients treated by mental health trained healthcare workers [23]. This can be explained by the fact that the decision making ability of patients abusing substances is altered and this facilitates poor treatment adherence [13]. Inline to this, the previous studies also reported that patients with no bereavement concern were less likely to experience loss to follow up while patients with mental status not at ease were at increased risk of defaulting from treatment [50, 51].

It was evidenced that advanced clinical stage such as poor baseline functional status, WHO clinical stage III or IV, suboptimal ART adherence, presence of one or more opportunistic infections and being underweight had higher risk of patient attrition. Such findings are similar to findings from studies in Ethiopia [83], Malawi [86], Guinea-Bissau [82] and Asia Pacific region [72]. The reasons for patients to be non-adherent were forgetfulness, side effects, feeling sick and running out of medication [87].

Limitation of the study
Original articles used different length of follow up period that had variable outcomes of attrition. Moreover, studies conducted across different treatment guidelines revision may affect patient retention and treatment outcome.

Conclusion
About two third of HIV patients were retained in care. The most common cause of attrition among HIV positive people in Ethiopia were loss to follow up, transfer out and death respectively. It can be concluded that Ethiopia has long to walk to achieve the minimum targets of patient retention achieved by most of low income countries. There were increased attrition rate for longer period of follow up that need due attention from clinicians. Due to change of treatment eligibility criteria from time to time and varying definitions of loss to follow up, it is necessary to reconsider the definitions of LTFU. Moreover, tracing studies are necessary to rule out final destination of loss to follow up patients. Social support is necessary for all HIV patients and encouraging disclosure to family members. This also implied HIV patients require mental health interventions in addition to the medical model of treatment. Patients with poor drug adherence, advanced HIV disease stage, opportunistic

### Table 3 Socio-demographic factors associated with HIV/AIDS patients’ attrition from care in Ethiopia (2005–2019)

| Variables               | No* | Sample | OR (95% CI) | I² (%) | P-value |
|-------------------------|-----|--------|-------------|-------|---------|
| Age in years            |     |        |             |       |         |
| 18–24                   | 8   | 12,482 | 1           | 99    | < 0.001 |
| > 24                    |     | 0.88 (0.27–2.89) |       |       |         |
| Sex                     |     |        |             |       |         |
| Female                  | 18  | 33,424 | 1           | 82.1  | < 0.001 |
| Male                    |     | 1.12 (0.97–5.45) |       |       |         |
| Marital status          |     |        |             |       |         |
| married                 | 13  | 18,911 | 1           | 90.8  | < 0.001 |
| Not married             |     | 1.52 (1.15–2.01)** |       |       |         |
| Employment status       |     |        |             |       |         |
| Employed                | 3   | 1887   | 1           | 70    | 0.036   |
| Not employed            |     | 1.27 (0.86–1.88) |       |       |         |
| Residence               |     |        |             |       |         |
| Urban                   | 2   | 12,735 | 1           | 93.3  | < 0.001 |
| Rural                   |     | 0.87 (0.43–1.78) |       |       |         |
| Education               |     |        |             |       |         |
| Educated                | 8   | 6016   | 1           | 96.7  | < 0.001 |
| Not educated            |     | 2.21 (0.90–5.45) |       |       |         |
| Disclosure status       |     |        |             |       |         |
| Disclosed               | 2   | 2008   | 1           | 71.1  | 0.063   |
| Not disclosed           |     | 6.36 (3.58–11.29)** |       |       |         |
| Substance use           |     |        |             |       |         |
| Yes                     | 2   | 815    | 1           | 75.5  | 0.044   |
| No                      |     | 0.41 (0.17–0.98)** |       |       |         |

No*---stands for numbers of articles
**Significant at p-value less than 0.05
**Table 4** Clinical factors associated with HIV/AIDS patients’ attrition from care in Ethiopia (2005–2019)

| Variables                        | No* | Sample | OR (95% CI) | I² (%) | P-value |
|----------------------------------|-----|--------|-------------|--------|---------|
| ART adherence                     |     |        |             |        |         |
| Good                             | 5   | 6080   | 1           | 98.1   | < 0.001 |
| Poor/fair                        | 660 | (1.41–30.97)** |        |        |         |
| Functional status                |     |        |             |        |         |
| Working                          | 12  | 9954   | 1           | 92.1   | < 0.001 |
| Ambulatory/bedridden              | 2.11(1.33–3.34)** |        |        |         |
| Opportunistic disease            |     |        |             |        |         |
| Yes                              | 8   | 7574   | 1           | 94.3   | < 0.001 |
| No                               | 0.52(0.30–0.90)** |        |        | < 0.001 |
| Recorded appointment             |     |        |             |        |         |
| Yes                              | 2   | 2518   | 1           | 97.6   |         |
| No                               | 0.7 (0.17–2.88) |        |        |         |
| BMI                              |     |        |             |        |         |
| Normal (> 18.5)                  | 4   | 2260   | 1           | 70.7   | 0.017   |
| Underweight (< 18.5)             | 2.21 (1.45–3.39)** |        |        |         |
| side effects                      |     |        |             |        |         |
| Yes                              | 2   | 1196   | 1           | 98.8   | < 0.001 |
| No                               | 0.83 (0.03–26.98) |        |        |         |
| INH                              |     |        |             |        |         |
| Took INH                         | 4   | 2275   | 1           | 97.7   | < 0.001 |
| Not took INH                     | 3.42 (0.57–20.51) |        |        |         |
| Health facility                  |     |        |             |        |         |
| Health center                    | 2   | 11,717 | 1           | 84.5   | 0.011   |
| Hospital                         | 1.23 (0.58–2.62) |        |        |         |
| Baseline WHO stage               |     |        |             |        |         |
| I and II                         | 12  | 21,509 | 1           | 92     | < 0.001 |
| III and IV                       | 1.85 (1.36–2.51)** |        |        |         |
| Baseline CD4 level               |     |        |             |        |         |
| < 200                            | 8   | 19,134 | 1           | 98.3   | < 0.001 |
| ≥ 200                            | 1.09 (0.49–2.41) |        |        |         |
| Hemoglobin                       |     |        |             |        |         |
| Anemic (< 10 g/mI)               | 2   | 815    | 1           | 0      | 0.35    |
| Normal (> 10 g/mI)               | 0.29 (0.20–0.42)** |        |        |         |

No*—stands for numbers of articles, ** significant at p-value < 0.05

infection, poor functional status (ambulatory or bedridden), underweight and anemic patients need special attention that includes adequate adherence preparation and nutritional intervention. In general it was evidenced that number of socio-demographic determinants prone patients for loss to follow up while the clinical factors leads to death. Hence, in order to achieve the desired level of patient retention in clinical care, a comprehensive interventions which are targeted at socio-demographic, clinical, laboratory and behavioral factors is necessary.
6. Abougi LL, Smith C, McFarland EJ. Retention of HIV-infected children in the first 12 months of anti-retroviral therapy and predictors of attrition in resource limited settings: a systematic review. PLoS One. 2016;11(6):e0156506.

7. Westerlund E, et al. Pre-ART retention in care and prevalence of tuberculosis among HIV-infected children at a district hospital in southern Ethiopia. BMC Pediatr. 2014;14(1):2250.

8. Ahmed I, et al. Predictors of loss to follow-up before HIV treatment initiation in Northwestern Ethiopia: a case control study. BMC Public Health. 2013;13(1):867.

9. Asefa Y, et al. Performance of the antiretroviral treatment program in Ethiopia, 2005-2015: strengths and weaknesses toward ending AIDS. Int J Infect Dis. 2017;60:7-6.

10. Tinuneh YM, et al. Retention in care among HIV-infected adults in Ethiopia, 2005-2011: a mixed-methods study. PLoS One. 2016;11(6):e0156619.

11. Bezabhe WM, et al. Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: a qualitative study from Ethiopia. PLoS One. 2014;9(3):e97353.

12. Asefa Y, et al. Scaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005-2013. Glob Health Dis. 2014;10(1):43.

13. Gesessew HA, et al. Discontinuation from antiretroviral therapy: a continuing challenge among adults in HIV care in Ethiopia: a systematic review and meta-analysis. PLoS One. 2017;12(12):e0196951.

14. Moheir D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.

15. Munn Z, et al. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evidence-Based Healthcare. 2015;13(3):147–53.

16. Seifu W, Ali W, Meresa B. Predictors of loss to follow up among adult clients attending antiretroviral treatment at Karamara general hospital, Jigjiga town, eastern Ethiopia, 2015: a retrospective cohort study. BMC Infect Dis. 2018;18(1):280.

17. Assemie MA, Muchie KE, Ayele TA. Incidence and predictors of loss to follow up among HIV-infected adults at Pawi general hospital, Northwest Ethiopia: competing risk regression model. BMC Res Notes. 2018;11(1):287.

18. Abebe N, et al. Survival status of HIV positive adults on antiretroviral treatment in Debere Markos referral hospital, Northwest Ethiopia: retrospective cohort study. Pan African Med J. 2014;17:88.

19. Peters JL, et al. Assessing publication bias in meta-analyses in the presence of between-study heterogeneity. J Royal Stat Soc. 2010;173(3):575–91.

20. Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95(449):89–98.

21. Higgins JP, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557.

22. Molla Yigzaw GD, Tesema C. Incidence and predictors of loss to follow-up among HIV-infected adults after initiation of first line anti-retroviral therapy at University of Gondar comprehensive specialized hospital Northwest Ethiopia, 2018: retrospective follow up study. BMC Res Notes. 2019;12(1):111.

23. Gezae KE, Abebe HT, Gebretsadik LG. Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009–2016: survival model approach. BMC Infect Dis. 2019;19(1):107.

24. Chaka TE, Abebe TW, Kassa RT. Option B+ prevention of mother-to-child transmission of HIV/AIDS service intervention outcomes in selected health facilities, Addama town, Ethiopia. HIV/AIDS (Auckland, NZ). 2019;11:77.

25. Tadege M. Predictors associated with HIV/AIDS patients dropout from antiretroviral therapy at Mettu Karl Hospital, Southwest Ethiopia. BMC Res Notes. 2019;12(1):332.

26. Awoke T, et al. Modeling outcomes of first-line antiretroviral therapy and rate of CD4 counts change among a cohort of HIV/AIDS patients in Ethiopia: a retrospective cohort study. PLoS One. 2016;11(12):e0168323.

27. Ayele T, et al. Treatment outcomes and their determinants in HIV patients on anti-retroviral treatment program in selected health facilities of Kembata and Hadiya zones, southern nations, nationalities and peoples region, Ethiopia. BMC Public Health. 2015;15(1):826.

28. Darmew B, Mengistie B, Almeayehu T. Survival and determinants of mortality in adult HIV/AIDS patients initiating antiretroviral therapy in Somali Region, Eastern Ethiopia. Pan African Med J. 2015;22(1):138.

29. Tadege M. Time to death predictors of HIV/AIDS infected patients on antiretroviral therapy in Ethiopia. BMC Res Notes. 2018;11(1):761.

30. Mekonnen E, et al. Reasons and predictors for antiretroviral therapy change among HIV-infected adults at south West Ethiopia. BMC Res Notes. 2018;11(1):351.

31. Ahmed A, et al. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-East Ethiopia: a retrospective cohort study. BMJ Open. 2018;8(2):e016961.

32. Mekuria LA, et al. High rates of virological suppression in a cohort of human immunodeficiency virus-positive adults receiving antiretroviral therapy in Ethiopian health centers irrespective of concomitant tuberculosis. In Open forum infectious disease. America Oxford University Press; 2014.

33. Berheto TM, Haile DB, Mohammed S. Predictors of loss to follow-up in patients living with HIV/AIDS after initiation of antiretroviral therapy. N Am J Med Sci. 2014;369(4):453.

34. Asefa Y, et al. Outcomes of antiretroviral treatment program in Ethiopia: retention of patients in care is a major challenge and varies across health facilities. BMC Health Serv Res. 2011;11(1):381.

35. Balcha TT, Jeppsson A. Outcomes of antiretroviral treatment: a comparison between hospitals and health centers in Ethiopia. J Int Assoc Phys AIDS Care. 2010;9(5):318–24.

36. Mekonnen N, et al. Incidence and predictors of loss to follow-up among HIV infected adults after initiation of first line anti-retroviral therapy at University of Gondar comprehensive specialized hospital Northwest Ethiopia, 2015: retrospective follow up study. BMC Infect Dis. 2019;19(1):107.

37. Chaka TE, Aweke TW, Kassa RT. Option B+ prevention of mother-to-child transmission of HIV/AIDS service intervention outcomes in selected health facilities, Addama town, Ethiopia. HIV/AIDS (Auckland, NZ). 2019;11:77.

38. Tadege M. Predictors associated with HIV/AIDS patients dropout from antiretroviral therapy at Mettu Karl Hospital, Southwest Ethiopia. BMC Res Notes. 2019;12(1):332.

39. Awoke T, et al. Modeling outcomes of first-line antiretroviral therapy and rate of CD4 counts change among a cohort of HIV/AIDS patients in Ethiopia: a retrospective cohort study. PLoS One. 2016;11(12):e0168323.

40. Ayele T, et al. Treatment outcomes and their determinants in HIV patients on anti-retroviral treatment program in selected health facilities of Kembata and Hadiya zones, southern nations, nationalities and peoples region, Ethiopia. BMC Public Health. 2015;15(1):826.

41. Darmew B, Mengistie B, Almeayehu T. Survival and determinants of mortality in adult HIV/AIDS patients initiating antiretroviral therapy in Somali Region, Eastern Ethiopia. Pan African Med J. 2015;22(1):138.

42. Tadege M. Time to death predictors of HIV/AIDS infected patients on antiretroviral therapy in Ethiopia. BMC Res Notes. 2018;11(1):761.

43. Beyene E, et al. Reasons and predictors for antiretroviral therapy change among HIV-infected adults at south West Ethiopia. BMC Res Notes. 2018;11(1):351.

44. Ahmed A, et al. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-East Ethiopia: a retrospective cohort study. BMJ Open. 2018;8(2):e016961.

45. Mekuria LA, et al. High level of virological suppression among HIV-infected adults receiving combination antiretroviral therapy in Addis Ababa. PLoS One. 2015;10(6):e0123649.

46. Assefa Y, et al. Brief report: long-term outcomes and their determinants in patients on antiretroviral treatment in Ethiopia, 2005/6–2011/12 a retrospective cohort study. JAIDS J Acquir Immune Defic Syndr. 2015;70(4):414–9.

47. Mekuria LA, et al. Retention in HIV care and predictors of attrition from care among HIV-infected adults receiving combination anti-retroviral therapy in Addis Ababa. PLoS One. 2015;10(6):e0123649.

48. Asefa Y, et al. Brief report: long-term outcomes and their determinants in patients on antiretroviral treatment in Ethiopia, 2005/6–2011/12 a retrospective cohort study. JAIDS J Acquir Immune Defic Syndr. 2015;70(4):414–9.

49. Mekuria LA, et al. Retention in HIV care and predictors of attrition from care among HIV-infected adults receiving combination anti-retroviral therapy in Addis Ababa. PLoS One. 2015;10(6):e0123649.

50. Asefa Y, et al. Brief report: long-term outcomes and their determinants in patients on antiretroviral treatment in Ethiopia, 2005/6–2011/12 a retrospective cohort study. JAIDS J Acquir Immune Defic Syndr. 2015;70(4):414–9.
52. Deribe K, et al. Defaulter from antiretroviral treatment in Jimma university specialized hospital, Southwest Ethiopia. Tropical Med Int Health. 2010;13(3): 328–33.
53. Bucciarini R, et al. Predictors of attrition from care at 2 years in a prospective cohort of HIV-infected adults in Tigray, Ethiopia. BMJ Glob Health. 2017;2(3):e000325.
54. Teshome W, et al. Do loss to follow-up and death rates from ART care vary across primary health care facilities and hospitals in south Ethiopia? A retrospective follow-up study. HIV/AIDS (Auckland, NZ). 2015;7:167.
55. Bucciarini R, et al. Retention in care of adult HIV patients initiating antiretroviral therapy in Tigray, Ethiopia: a prospective observational cohort study. PLoS One. 2015;10(10):e0136117.
56. Lifson AR, et al. Implementation of a peer HIV community support worker program in rural Ethiopia to promote retention in care. J Int Assoc Providers AIDS Care (JIAPAC). 2017;16(1):75–80.
57. Bezabhe WM, et al. Antiretroviral adherence and treatment outcomes among adult Ethiopian patients. AIDS Care. 2016;28(8):1018–22.
58. Teleke NF, et al. Baseline predictors of antiretroviral treatment failure and loss to follow-up in a multicenter countrywide HIV-1 cohort study in Ethiopia. PLoS One. 2016;11(7):e0160005.
59. Wubshet M, et al. Death and seeking alternative therapy largely accounted for loss to follow-up of patients on ART in Northwest Ethiopia: a community tracking survey. PLoS One. 2013;8(3):e59197.
60. Wubshet M, et al. High loss to followup and early mortality create substantial reduction in patient retention at antiretroviral treatment program in north-West Ethiopia. Ims aids. 2012;2012:72120.
61. Matthew P, Fox D, I. 1, 2, 3 and Sydney Rosen MPA1,3, retention of adult patients on antiretroviral therapy in low-and-middle-income countries: systematic review and meta-analysis 2008–2013. J Acquir Immune Defic Syndr. 2015;69:453.
62. Asella Y, et al. How to improve patient retention in an antiretroviral treatment program in Ethiopia: a mixed-methods study. BMC Health Serv Res. 2014;14(1):45.
63. Lifson AR, et al. Barriers to retention in care as perceived by persons living with HIV in rural Ethiopia: focus group results and recommended strategies. J Int Assoc Providers of AIDS Care (JIAPAC). 2013;12(1):32–8.
64. Mehta KG, et al. Drug adherence rate and loss to follow-up among people living with HIV/AIDS attending an ART Centre in a tertiary government Hospital in Western India. J Family Med Primary Care. 2016;5(2):266.
65. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Tropical Med Int Health. 2010;15:1–5.
66. du Tuit E, et al. Missed opportunities for retention in pre-ART Care in Cape Town, South Africa. PLoS One. 2014;9(5):e96867.
67. Rosen S, Fox MP, Gili CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4(10):e298.
68. Umekonkonwo CD, et al. Retention in care and adherence to HIV and AIDS treatment in Anambra state Nigeria. BMC Infect Dis. 2019;19(1):654.
69. Hønge BL, et al. Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open. 2013;2(10)e003499.
70. Bhende BL, et al. Death to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis. J Int Assoc Providers AIDS Care (JIAPAC). 2013;12(1):32–8.
71. Lifson AR, et al. Retention in care: a systematic review. AIDS Res Treatment. 2017;2017:5415298.
72. Layer EH, et al. Multiple factors affecting entry into and engagement in the HIV continuum of Care in Iringa, Tanzania. PLoS One. 2014;9(6):e104961.
73. Bulsara SM, Wainberg ML, Newton-John TR. Predictors of adult retention in HIV care: a systematic review. AIDS Behav. 2018;22(3):752–64.
74. Tsva H, et al. Loss to follow-up before and after initiation of antiretroviral therapy in HIV facilities in Lilingwe, Malawi. PloS One. 2018;13(1):e0188488.
75. Tegegne AS, Ndlovu P, Zewotir T. Factors affecting first month adherence due to antiretroviral therapy among HIV-positive adults at Felege Hiwot teaching and specialized hospital, North-Western Ethiopia: a systematic study. BMC Infect Dis. 2018;18(1):83.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions